Permitted Disclosure of Information. Notwithstanding anything to the contrary contained in Section 7.1, a Party receiving Confidential Information of the other Party may disclose such information to the extent that such Confidential Information:
Permitted Disclosure of Information. The provisions of this Article 13 shall not apply to Information which:
Permitted Disclosure of Information. (a) Notwithstanding anything to the contrary contained in Section 5.1 or the Confidentiality Agreement, Cephalon may disclose any Confidential Information of Champions:
Permitted Disclosure of Information. The Parties agree that Exelixis shall have access to, and may use and disclose the Clinical Plan and any existing or newly generated data or intellectual property developed with respect to the Programs (i) to GlaxoSmithKline or the Exelixis-GlaxoSmithKline Collaboration Committee in accordance with the mutual agreements of Exelixis and GlaxoSmithKline, (ii) to obtain the assistance of one or more third parties to develop and/or commercialize the Programs subject to the terms of this Agreement, the other Operative Documents and appropriate confidentiality agreements pursuant to Section 10.1 or as approved by Symphony Evolution, and (iii) through press releases, public presentations or other appropriate public disclosures; provided that all such disclosure under this Section 10.2 shall be subject to the terms of the Confidentiality Agreement.
Permitted Disclosure of Information. Notwithstanding anything to the contrary contained in Section 5.1, a Party receiving Information of the other Party may disclose such Information: required to be submitted by the recipient to governmental or other Regulatory Authorities to obtain patents (including disclosure to U.S. and foreign patent offices and patent counsel for purposes of patent prosecution) or to facilitate the issuance of any necessary registrations or filings in connection with conducting clinical trials for a Product, or developing, manufacturing or commercializing a Product, provided that such disclosure may be only to the extent reasonably necessary to obtain patents or authorizations and that reasonable steps shall be taken to assure confidential treatment of such Information; by either Party to its permitted Sublicensees, agents, consultants, Affiliates and/or other Third Parties to the extent reasonably necessary for the research and development, manufacturing, registration and/or marketing of a Product (or for such parties to determine their interest in performing such activities) in accordance with this Agreement on the condition that such disclosure may be only to the extent reasonably necessary for such activities and that such Third Parties agree to be bound by the confidentiality and non-use obligations contained within this Agreement; provided that the term of confidentiality for such Third Parties shall be no less than seven (7) years; or if required to be disclosed by law or court order; provided that notice is promptly delivered to the other Party in order to provide an opportunity to challenge or limit the disclosure obligation; and provided further the Party required to disclose cooperates with the other Party in limiting disclosure to the extent so required. Information that is disclosed by judicial or administrative process shall remain otherwise subject to the confidentiality and non-use provisions of Sections 5.1 and 5.2 and the Party disclosing Information pursuant to law or court order shall take all steps reasonably necessary, including obtaining an order of confidentiality, to ensure the continued confidential treatment of such Information.
Permitted Disclosure of Information. 1. Notwithstanding the foregoing, the Receiving Party or its Representatives may disclose the Information of the Disclosing Party if such disclosure is required pursuant to a court order or applicable law (including without limitation pursuant to applicable securities laws, regulations or rules), provided:
Permitted Disclosure of Information. The Parties agree that Isis shall have access to, and may use and disclose the Development Plan and any existing or newly generated data or intellectual property developed with respect to the Programs (i) to obtain the assistance of one or more third parties to develop and/or commercialize the Programs subject to the terms of this Agreement, the other Operative Documents and appropriate confidentiality agreements pursuant to Section 10.1 or as approved by Symphony GenIsis, (ii) to use such intellectual property for all purposes not licensed exclusively to Symphony GenIsis under the Novated and Restated Technology License Agreement, and (iii) through press releases, in public presentations or as part of other appropriate public disclosures; provided that all such disclosure under this Section 10.2 shall be subject to the terms of the Confidentiality Agreement.
Permitted Disclosure of Information. Notwithstanding SECTION 4.1, a Party receiving information from another Party may disclose such information if required to be disclosed by law or court order, provided that notice is promptly delivered to the non-disclosing Party in order to provide an opportunity to challenge or limit the disclosure obligations; provided, however, without limiting any of the foregoing, it is understood that any Party may make disclosure of this Royalty Agreement and the terms hereof in a press release and in any filings required by the United States Securities and Exchange Commission and other regulatory agencies.
Permitted Disclosure of Information. Notwithstanding anything to the contrary contained in Section 5.1, NEUROGEN may disclose such Information: [***] Confidential treatment requested by Neurogen Corporation.
Permitted Disclosure of Information. The Parties agree that Dynavax shall have access to, and may use and disclose the Development Plan and any existing or newly generated data or intellectual property developed with respect to the Programs (i) to obtain the assistance of one or more third parties to develop and/or commercialize the Programs subject to the terms of this Agreement, the other Operative Documents and appropriate confidentiality agreements pursuant to Section 10.1 or as approved by Symphony Dynamo, (ii) to use such intellectual property for all purposes not licensed exclusively to Symphony Dynamo under the Novated and Restated Technology License Agreement, and (iii) through press releases, in public presentations or as part of other appropriate public disclosures; provided that all such disclosure under this Section 10.2 shall be subject to the terms of the Confidentiality Agreement.
